Summary
Scleroderma is a rare disease that commonly involves the lungs in a variety of ways. These include interstitial lung disease, pulmonary vascular disease and bronchiolitis. Pulmonary hypertension is the leading cause of mortality in scleroderma. The treatment of scleroderma, generally, and its associated lung diseases, specifically, have not been well defined by controlled trials. However, the results of uncontrolled studies and an understanding of the pathological basis of scleroderma allow a rational choice of therapeutic options.
With our current limited knowledge, a reasonable approach is to treat progressive interstitial lung disease with immunosuppressive drugs such as cyclophosphamide and prednisone. Pulmonary vascular disease has a poor prognosis and therapy is currently limited, although new treatment strategies are on the horizon. Most promising is the recent development of locally administered therapies. These may overcome the frequent and excessive adverse effects that limit the use of potent systemically administered drugs.
Pulmonary involvement is a significant clinical problem in connective tissue diseases in general. In scleroderma, lung involvement is found in most, if not all, patients. [l] Although in the majority of patients it is asymptomatic, it is a major cause of morbidity and mortality. For example, pulmonary hypertension is now the single most common cause of death in scleroderrna. [2] In spite of the importance of pulmonary pathology in this disorder, there is a lack of well controlled prospective therapeutic studies, due in part to the relative rarity of scleroderma itself.
There are 2 major forms of scleroderma, a limited and a diffuse form. Co-association with other autoimmune syndromes, particularly with Sjogren's syndrome, is common. In a group of scleroderma patients, 15 to 25% had histological evidence of Sjogren's syndrome and 50% of them were anti-SS-A or SS-B positive.1 3 ] Even larger numbers of patients have clinically troublesome sicca symptoms. As in scleroderma, pulmonary pathology is a common accompaniment of Sjogren's syndrome) [4] [5] [6] [7] Therefore, it may be difficult to determine in any individual whether the underlying pulmonary pathology is due to scleroderma or Sjogren's syndrome. It is likely that some of the pulmonary abnormalities previously ascribed to scleroderma may in fact be due to Sjogren's syndrome,fI ,8] This review will focus on the therapy of the major pulmonary syndromes seen in scleroderma: interstitiallung disease, pulmonary hypertension and tracheobronchial involvement. However, in the clinical evaluation of shortness of breath in scleroderma, other significant aetiologies must be considered. These include cardiovascular disease, [9, IO] anaemia and, less commonly, respiratory tract infections, as well as disease-associated myopathic processes. Additionally, it must be remembered that the drugs used in the treatment of scleroderma can also cause pulmonary symptoms including chronic cough (ACE inhibitors) and interstitial lung disease (a rare complication of methotrexate, cyclophosphamide or penicillamine use).
Interstitial Lung Disease

Epidemiology
Abnormalities in respiratory function tests are found in the majority of patients with scleroderma) III The prevalence of interstitial lung disease has been reported to be as high as 50 [8, II] to 74%, [12] making it a relatively common phenomenon in a rare disease. It is likely that in the majority Brown & Breit of these patients the interstitial lung pathology is subclinical. Although in the early stages of interstitial lung disease patients may be completely asymptomatic, as they progress a dry cough, dyspnoea and a diminished exercise capacity commonly occur. Increasing dyspnoea is the hallmark of an ongoing inflammatory process in the lung.
Investigation
The aim of investigations should be to define the presence of interstitial lung disease and then determine whether an active inflammatory process is present. The detection of an ongoing inflammatory response in the lung is suggestive of progressive disease, which is more likely to require treatment. The gold standard for the evaluation of interstitial lung disease is the open lung biopsy, but this procedure has significant morbidity.
The first available investigative tool was the chest x-ray. While showing abnormalities in up to 60% of patients, [13] it is relatively insensitive and is incapable of delineating active, progressive disease. Respiratory function tests, particularly gas diffusion, are relatively simple and are a more sensitive guide to interstitial pulmonary disease. However, on a single testing, respiratory function tests cannot identify patients with an ongoing inflammatory process, nor can they usually distinguish between pulmonary vascular disease and interstitial lung disease. An isolated marked decrease in gas diffusion with otherwise normal respiratory function tests does, however, suggest isolated pulmonary vascular disease. [14, 15] More recently, other testing procedures that offer some additional advantages have been used. These include bronchoalveolar lavage, DTPA scanning, gallium lung scanning and high resolution computerised tomography of the lung. While bronchoalveolar lavage is particularly useful in the investigation of interstitial lung disease, it is only suitable for use in large centres experienced in the handling and analysis of samples)16,17] However, high resolution computerised tomography has been shown in various studies to be a reasonable predictor of histology and bronchoalveolar lavage findings.[l8-20] It is noninvasive, easy to perform and of value for monitoring disease activity. [21] 
.3 Pathogenesis
It is not within the scope of this paper to review the pathogenesis of interstitial lung disease in scleroderma, which has been reviewed extensively elsewhere.[l, 22, 23] Briefly, this disorder is due to an inflammatory process, triggered by unknown factors, in which continued production of cytokines such as platelet-derived growth factor and transforming growth factor-~ eventually leads to fibrosis. [24] [25] [26] On bronchoalveolar lavage, this inflammatory process is largely typified by 2 abnormalities, either neutrophilia or lymphocytosis. Very early in 1he disease there may be a relative eosinophilia. [20] The 2 main cellular infiltrate types rarely coexist; the neutrophilic and the lymphocytic forms 'Jf alveoli tis probably represent different pathogenic processes within the lung. The neutrophilic alveolitis is associated with a greater decrease in gas diffusion, but less avid gallium uptakeP7,28] It is similar to idiopathic pulmonary fibrosis, but has a somewhat better prognosis [29] and is probably directly related to scleroderma. The lymphocytic alveolitis may be due to co-associated Sjogren's syndrome rather than scleroderma itself. It is generally thought to have a better prognosis with a lesser tendency to fibrosis and less depression in gas diffusion, but more avid gallium uptake. [8, 27, 30] 
Treatment
There have been few, if any, prospective controlled trials of the treatment of scleroderma interstitial lung disease. The only drug that has been comprehensively shown to be of benefit, with prolonged usage (>2.3 years), is penicillamine. Its use is associated with stabilisation or modest improvement only in gas diffusion. Clinical trials of other agents are generally marred by small numbers and the often long length of time between disease onset and treatment. It seems probable that immunosuppressive treatment would be more effective early in the disease process. Long-standing disease, with established fibrosis and often reduced inflammatory actIVIty, would be expected to respond less favourably to this type of therapy. These factors make it difficult to interpret the conflicting results of trials using immunosuppressive treatmentJ33, 34 1 However, some small uncontrolled studies suggest that cyclophosphamide and prednisone may be effective.
Cyclophosphamide is the most potent commonly used immunosuppressive drug. In small studies, this compound combined with prednisone may be beneficial with improvement in forced vital capacity (FVC) and gas diffusionJ13,3 5 1 Steen et aIJ 36 1 conducted a retrospective study of 363 patients, of whom 122 fulfilled criteria for drug therapy after follow-up deterioration in FVC, which was initially below 70% of predicted. The treatment groups were stratified between high dose prednisone (21 patients), immunosuppression other than cyclophosphamide (16 patients), cyclophosphamide (14 patients) and no drug (34 patients). Analysis revealed that patients in the cyclophosphamide-treated group had significant improvement in FVC by a mean of 435 ml/year, but no significant change in gas diffusion. Patients with early disease had a greater chance of responding to any drug.
In another uncontrolled study, [37] 18 patients with pulmonary fibrosis were treated with cyclophosphamide for at least 1 year. The median disease duration prior to treatment was 2.5 years. 14 of the 18 patients had an increase in their FVC, from 74 to 80% of predicted, and their overall skin score improved. Patients with serological evidence of inflammation, as measured by raised erythrocyte sedimentation rate (ESR) and C-reactive protein, had a greater likelihood of response and, overall, larger increase in vital capacity. There was no significant change in gas diffusion, but there was subjective improvement in breathlessness.
Another very potent but less commonly used immunosuppressive drug is chlorambucil. A doubleblind, randomised, placebo-controlled trial involving 65 patients using chlorambucil was conducted over a 3-year period.£3 41 No benefit over placebo was demonstrated. 11 patients had clinical evidence of interstitial pulmonary disease in the treatment group (rales or shortness of breath), with 13 patients having similar clinical findings in the placebo group. The mean gas diffusion of the treatment versus placebo group was 62 and 58% of predicted normal values, respectively. Patients were selected according to the American Rheumatism Association (1980) criteria. This study has several problems. Firstly, the mean disease duration was 7.5 years, with the majority of patients having disease for >5 years. Analysis of patients with disease <5 years showed a significant improvement in exercise tolerance in the chlorambucil group. There was no significant improvement in other pulmonary function, which may be due, in part, to the long pretreatment disease duration. It is difficult to draw any conclusions as to the benefit of chlorambucil for interstitial lung disease in this trial for 2 reasons. Firstly, interstitial lung disease was not a major selection criterion. Also, the likelihood of established fibrosis in long-standing disease responding to immunosuppression is low.
In a number of trials discussed below, skin thickness is used as the major criterion of response. It would seem reasonable, with the lack of specific pulmonary-directed trials, to extrapolate that a favourable response in the skin may also be associatedwith a good response in the lung. This may be expected as the pathological mechanisms in the skin are similar to those in the lung.
Another commonly used, less potent and less toxic drug is methotrexate, which has been shown to be of possible benefit in scleroderma. [38] The number of patients in studies has been small, and only 1 of the trials has been published formally. Van den Hoogen et al. f39 ] performed a pilot study of 8 un selected scleroderma patients, 4 of whom had interstitial pulmonary disease as defined by respiratory function tests. The mean disease duration was 29 months. Seven patients completed the study, and I patient discontinued due to pulmonary aspergillosis. Another patient experienced a continued rapid deterioration in all parameters of disease which commenced before treatment started, while in all the other patients respiratory function remained stable with improvement in skin manifestations. Pulmonary function tests were not listed, making it difficult to draw conclusions regarding the effect of methotrexate on lung disease.
Other immunomodulatory therapies such as interferon-a and interferon-y inhibit in vitro fibroblast collagen production, and for this reason have been used in uncontrolled trials to assess effects on skin thickening.[40,4I J Both have yielded similar results. After the 6 months of the trial, interferon-a induced improvement in skin thickening in lO of 14 patients and seemed to stabilise the disease. In 12 of the 14 patients who had respiratory function tests performed, there were no significant changes. Unfortunately, the pre-entry respiratory function tests were not included, making it difficult to draw any conclusions as to the effect on lung pathology.
In other attempts to modulate scleroderma disease activity via manipulation of the immune system, cyclosporin and anti thymocyte globulin have been used with beneficial effects on the skin. [42] [43] [44] 10 patients satisfying the American Rheumatism Association (1980) criteria were treated with cyclosporin over 48 weeks. There was no significant change in the pulmonary function tests of the 7 patients who had established pulmonary involvement (total lung capacity <80% predicted, gas diffusion <70% predicted) except in gas diffusion. In the 6 patients who responded to cyclosporin, gas diffusion improved (p < 0.04). Therefore, cyclosporin may be beneficial in lung disease over longer periods.
A trial of antithymocyte globulin was conducted in 7 patients with treatment-resistant scleroderma.l 42 ,43] Of the 3 patients who were specifically treated for interstitial lung disease, there was amelioration of lung disease in 2, as documented by increased lung capacity and gas diffusion. Immunosuppressive agents had previously been used in these patients with little effect.
While there is a lack of compelling data to support the various treatments available, there is some evidence for the efficacy of immunosuppressive drugs. Faced with a difficult clinical problem, it would seem reasonable to formulate therapeutic strategies from what is known of disease pathogene~is, data on therapy of immunopathologically similar diseases and limited data on the therapy of scleroderma itself. This would suggest the use of immunosuppressive therapy for serious disease. Because of the toxic nature of the drugs used, a decision should be based on the presence of active disease with clinical evidence of progression. Cyclophosphamide and prednisone would appear to be the agents likely to provide the greatest chance of response. One strategy to minimise use of cyclophosphamide, a potentially toxic drug, is to substitute methotrexate after a period of stabilisation of lung function, usually 6 to 12 months. Methotrexate has been used for prolonged periods in the treatment of rheumatoid arthritis and is substantially l)etter tolerated than cyclophosphamide; there is .orne evidence that it may be effective therapy for ~arly sclerodermaJ38,39]
Bronchiolitis
Epidemiology and Investigation
Small airways disease in scleroderma has been recognised for some time, [45] [46] [47] with bronchiolitis occurring in 13 to 25% [14, 27] of patients. While bronchiolitis is quite common, the majority of patients are probably asymptomatic. Histopathologically, the terminal and respiratory bronchioles are affected by a chronic submucosal inflammatory infiltrate.l 48 ] Typically, respiratory function tests demonstrate depression in the mid-maximal expiratory flow rate, out of proportion to depressed gas transfer and evidence of restricted lung function, and there is an association with lavage lymphocytosis. [27] With the increased frequency of Sjogren's syndrome in scleroderma patients, the association between scleroderma and bronchiolitis may well be due to Sjogren's syndrome. [5, 27] Penicillamine and smoking are both suggested as factors in the pathogenesis of bronchiolitis, [49] but do not account for most cases.
Treatment
Severe bronchiolitis in the absence of interstitial pulmonary disease is unusual. When treatment is necessary, there is evidence that the condition is corticosteroid-responsive. [46] Patients should be commenced on a dosage of corticosteroid sufficient to suppress symptoms, with a gradual reduction in dosage as time and response allow.
Isolated Pulmonary HypertenSion
Epidemiology
In scleroderma, pulmonary hypertension may occur secondary to interstitial lung disease or as an isolated primary process affecting the pulmonary vessels, without involvement of lung parenchyma. Isolated pulmonary hypertension is predominantly associated with the limited form of scleroderma. It is this isolated form of pulmonary hypertension that will be considered further.
Pulmonary vascular changes have been noted in 30% of autopsies of patients with scleroderma.l 48 ] This finding was associated with a myointimal mononuclear infiltrate, raising the possibility of an inflammatory process affecting these vessels. In the largest published study of respiratory function in scleroderma (815 participants), an isolated depression in gas diffusion was found in 19%. Of these, 5% had clinical evidence of pulmonary hypertension at presentation and 11 % progressed to pulmonary hypertension after a mean of 7.2 years of follow-up. [50] In another study, there was a 75% success rate in the detection of pulmonary hypertension, with the combination of isolated decreased gas diffusion «43% of predicted), x-ray changes (enlarged pulmonary artery) and echocardiological changes. Clinical pulmonary hypertension was associated with a gas diffusion <48% of predicted. All of the patients had the limited form of scleroderma and died within 2 years of diagnosis of pulmonary hypertension. [14] 
3,2 Investigation
An isolated depression of gas diffusion has been suggested as an early sign of pulmonary hypertension, and may present in entirely asymptomatic patients. This sign, combined with electrocardiological, echocardiological and chest x-ray changes are of assistance. However, the definiti ve investigation is right heart catheterisation. It is a valuable and conclusive test that should be undertaken in situations of doubt.
3,3 Pathogenesis in Scleroderma
The aetiology of pulmonary hypertension is not fully understood, but the endothelins, a potent family of endothelial-derived cytokines, have been incriminated in its pathogenesis. Endothelins are both vasospastic and proliferative to smooth muscle, and are thought to also be involved in the generalised arterial changes of scleroderma.f 51 -53 ] The level of endothelin is raised in scleroderma generally, but higher levels are found in patients with pulmonary hypertension or renal vascular arteriopathy.f 51 ] There have been several studies linking pulmonary hypertension in scleroderma to local pulmonary vascular production of endothelin. This strongly supports a model in which localised endothelin synthesis produces pulmonary vasoconstriction and eventually proliferation of smooth muscle. [52, 53] 
3,4 Treatment
The prognosis of the scleroderma patient with pulmonary hypertension is poor, with a 2-year survival rate of 40%. [54] Current treatment modalities are of limited efficacy. They include continuous ambulatory oxygen therapy, [55] calcium channel blockers such as nifedipine [56, 57] or continuous intravenous prostacyclin (epoprostenol) infusion.f 58 -60] The use of other vasodilators has been reported, but there does not seem to be any evidence of benefit, and in the case of the nonselective agents there may be worsening of hypoxaemia due to the increase of ventilation perfusion mismatching. Recent concentration on endothelin has led to the syn-thesis of endothelin receptor antagonists, which reverse the pulmonary changes in a rat model of hypoxic pulmonary hypertension, [54] but they are not yet available, except in a limited phase I trial. [54] At the present time, the only 2 interventions with some proven benefit are calcium channel blockers, particularly nifedipine, and anticoagulation with warfarin in patients without contraindications.f54] Additionally, there are 2 trials showing benefit with continuous intravenous prostacyclin.[59. 6 01 These systemically administered therapies are all limited either by a lack of efficacy or adverse effects related to dilation of the systemic as well as the pulmonary vasculature.
In an effort to maximise pulmonary vasodilatation and minimise systemic adverse effects, more rational approaches are being adopted that depend on local administration of vasodilators. Inhaled nitric oxide has been shown to reduce pulmonary vascular resistance in the short term with few adverse effects, although there may be rebound vasospasm. [54] Recently, extended benefit has been reported with the use of an inhaled prostacyclin analogue, iloprost. By this route, iloprost produces local pulmonary effects without the systemic adverse effects of prostacyclin. [61] No prolonged trial has been undertaken to study long term survival, but clearly these approaches have some promise.
